ATAI Life Sciences N.V.

NASDAQ:ATAI   3:59:54 PM EDT
5.40
-0.56 (-9.40%)
Products

ATAI Life Sciences Announces FDA Investigational New Drug (Ind) Clearance For PCN-101 R-Ketamine Program

Published: 01/12/2022 14:24 GMT
ATAI Life Sciences N.V. (ATAI) - Atai Life Sciences Announces FDA Investigational New Drug (ind) Clearance for Pcn-101 R-ketamine Program.
Atai Life Sciences - Plans to Initiate Clinical Ddi Study in Early 2022 to Assess Pharmacokinetics of Pcn-101 When Used Concurrently With Other Drugs.
Atai Life Sciences NV - Ddi Trial Will Complement Existing Phase 2a Trial in Treatment-resistant Depression (trd) Recently Initiated in Europe.